Meeting
2014 ASCO Annual Meeting
Prevalence of MET and HER2 biomarkers in stage IV gastric cancer.
Authors
Robert D. Loberg
Molecular Sciences & Computational Biology, Amgen, Inc., Thousand Oaks, CA
Robert D. Loberg , Rui Tang , Kelly Smith Oliner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 4048)
DOI
10.1200/jco.2014.32.15_suppl.4048
Abstract #
4048
Poster Bd #
135
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
First Author: Michael Alexander Gordon
Poster
2012 Gastrointestinal Cancers Symposium
Relationship between serum HER2 level and histologic HER2 status in patients with advanced/recurrent gastric cancer.
First Author: Takahide Sasaki
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Computational pathology–based HER2 quantification to identify novel biomarkers in gastric cancer (GC).
First Author: Ansh Kapil
Poster
2022 ASCO Annual Meeting
Assessment of a HER-2 scoring system and its correlation of HER2-targeting antibody-drug conjugate therapy in urothelial carcinoma.
First Author: Huizi Lei